Open Access Open Access  Restricted Access Subscription or Fee Access

Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug

Seema Manak, F. Akram, D. Inder


Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins i.e glucagon-like peptide1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Incretins augment the insulin release by a blood glucose-dependent mechanism. Generally DPP-IV enzyme is responsible for inactivating incretins and this enzyme inhibition will prolong and enhance the activity of GLP-1 and GIP. DPP-IV inhibitors increase post prandial insulin secretion, decreases glucagon secretion and seems to have beneficial effect on cardiovascular system, renal and hepatic insufficiencies. Being safe, tolerable and able to maintain consistent glycemic control without severe hypoglycemia and weight gain makes it unique and valuable in pharmacotherapy of Type 2 diabetes mellitus.


Keywords: Dipeptidyl peptidase IV inhibition, incretin, gliptin, oral antidiabetic drugs, Type-2 diabetes mellitus


Cite this Article

S. Manak, F. Akram, D. Inder. Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug. Research & Reviews: A Journal Pharmaceutical Science. 2020; 11(3): 1–6p.


Dipeptidyl peptidase IV inhibition, incretin, gliptin, oral antidiabetic drugs

Full Text:



  • There are currently no refbacks.

Copyright (c) 2020 Research and Reviews: A Journal of Pharmaceutical Science